益气活血壮骨方治疗气滞血瘀型原发I型骨质疏松症的临床研究  

Clinical efficacy of Yiqihuoxuezhuanggu Formula in PMO patients

作　　者：邓敦[1] 陈黎虬[1] 张维康[1] 颜海波[1] 王照晖[1] 陈笑宇[1] 施杞[2] 王拥军[2] 

机构地区：[1]温州医学院附属温岭医院 [2]上海中医药大学附属龙华医院,上海200032

出　　处：《中国临床药理学与治疗学》2013年第12期1383-1387,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：温岭市科技局重点科研项目(20100045);浙江省继续医学教育项目(20110407010)

摘　　要：目的:探讨益气活血壮骨方对气滞血瘀型原发I型骨质疏松症患者临床疗效和不良反应的影响。方法:选取2010年1月-2012年1月120例原发I型骨质疏松症患者,随机分为益气活血壮骨方组(研究组)、仙灵骨葆组(对照组),每组60例。连续给药12周后检测骨密度、骨钙素、1,25-(OH2)D3改变,临床症状改善及不良反应。结果:研究组骨密度、骨钙素及1,25-(OH2)D3含量高于对照组,临床症状改善优于对照组,差异有统计学意义(P<0.05)。结论:益气活血壮骨方对气滞血瘀型原发I型骨质疏松症患者可抑制骨吸收,促进骨形成,从而阻止骨量丢失,改善临床症状。AIM. To study the clinical efficacy and adverse reaction of Yiqihuoxuezhuanggu Formula in Qi stagnation and blood stasis primary osteoporosis（PMO） patients. METHODS： In this trial, PMO patients were randomly assigned into two groups： Yiqihuoxuezhuanggu Formula group, Xianlinggubao group. Medicines were given for 12 weeks. Bone metabolism, DEXA scanning, adverse reaction and serum data were determined. RESULTS： Compared with the control group, the expression of BMD, 1,25-（OH2 ） D3 and blood calcium in Yiqihuoxuezhuanggu Formula group were increased significantly, less adverse reaction （ P 〈 0.05 ）. CONCLUSION： Yiqihuoxuezhuanggu Formula shows on a better treatment in Qi stagnation and blood stasis PMO patients, its mechanism may be related to decreasing the bone resorption and promoting the bone formation, thus preventing the bone mass loss.

关 键 词：原发I型骨质疏松 气滞血瘀型 益气活血壮骨方 不良反应 

分 类 号：R589.5[医药卫生—内分泌]